financetom
Business
financetom
/
Business
/
Magnera's Q4 net sales, EBITDA rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Magnera's Q4 net sales, EBITDA rise
Nov 19, 2025 4:14 PM

Overview

* Outdoor apparel retailer Magnera ( MAGN ) posts Q4 net sales rise of 51% yr/yr, driven by Glatfelter merger and favorable currency impacts

* Adjusted EBITDA for Q4 up 36%

* Company repaid $50 mln term loan, reducing leverage

Outlook

* Magnera ( MAGN ) targets fiscal 2026 adjusted EBITDA of $380 mln - $410 mln

* Company expects fiscal 2026 free cash flow of $90 mln - $110 mln

Result Drivers

* GLATFELTER MERGER - Merger contributed $328 mln to net sales and $28 mln to adjusted EBITDA

* SELLING PRICE DECREASE - Lower raw material costs led to $35 mln decrease in selling prices

* ORGANIC VOLUME DECLINE - 3% organic volume decline due to market softness in Europe and competitive pressures in South America

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 $10 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the textiles & leather goods peer group is "buy"

* Wall Street's median 12-month price target for Magnera Corp ( MAGN ) is $13.00, about 38.8% above its November 19 closing price of $7.96

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Campbell's Tempers Fiscal 2025 Outlook After Second-Quarter Sales Miss
Campbell's Tempers Fiscal 2025 Outlook After Second-Quarter Sales Miss
Mar 5, 2025
10:01 AM EST, 03/05/2025 (MT Newswires) -- Campbell's (CPB), formerly known as Campbell Soup, on Wednesday reported fiscal second-quarter revenue that fell short of analysts' expectations, while the consumer packaged food firm cut its 2025 outlook. Net sales rose to $2.69 billion during the three months ended Jan. 26 from $2.46 billion a year earlier, but trailed the FactSet-polled consensus...
Sernova Secures $1 Million in Convertible Debt Financing
Sernova Secures $1 Million in Convertible Debt Financing
Mar 5, 2025
09:51 AM EST, 03/05/2025 (MT Newswires) -- Sernova Biotherapeutics (SVA.TO), a regenerative medicine company trading near 52-week lows, on Wednesday announced a $1 million unsecured convertible debenture financing with Dr. Steven Sangha, a Sernova ( SEOVF ) shareholder and board member. The debenture is repayable on March 4, 2027, unless earlier converted or redeemed, and carries a 15% interest rate....
Update: Thor Industries Swings to Fiscal Q2 Loss, Revenue Decreases; Adjusts 2025 Guidance
Update: Thor Industries Swings to Fiscal Q2 Loss, Revenue Decreases; Adjusts 2025 Guidance
Mar 5, 2025
10:05 AM EST, 03/05/2025 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph.) Thor Industries ( THO ) shares were down nearly 12% in recent Wednesday trading after the company swung to a Q2 loss and posted lower revenue. The company reported a fiscal Q2 loss of $0.01 per diluted share, swinging from earnings of $0.13...
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
Mar 5, 2025
DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer ( PFE ) and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna ( MRNA ). In a statement, the court in the city of Duesseldorf said that Pfizer ( PFE ) and BioNTech would have to provide information on earnings derived from the use of the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved